Latest From CeQur SA
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
The number of big medtech venture rounds, those worth at least $50 million, has decreased and plateaued over the past couple of years, but the overall dollars brought in by those scarce deals notably increased in 2015. And a few lucky medtech firms managed to grab more than $100 million from single fundraises last year.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
- Infusion Therapy Equipment and Supplies
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- CeQur SA
- Senior Management
Bradley Paddock, CEO
Douglas Gunthardt, EVP, CFO
Jay Warner, SVP, Clinical & Commercialization
Robert Farra, CTO
- Contact Info
Phone: (41) 41 500 4862
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.